BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18621563)

  • 1. Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis?
    Pasa S; Altintas A; Cil T; Ustun C; Bayan K; Danis R; Urakci Z; Tuzun Y; Ayyildiz O
    Int J Infect Dis; 2009 Jan; 13(1):e19-22. PubMed ID: 18621563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide for the treatment of multiple myeloma.
    Hattori Y; Iguchi T
    Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
    Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
    Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
    Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
    Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thalidomide for the treatment of refractory multiple myeloma].
    Kakimoto T; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
    Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
    Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department].
    Aimono Y; Sato W; Otani E; Isa S; Sawahata T; Onozaki M; Saito Y; Ebata S; Aoyama Y; Hakozaki M; Suzuki M; Kudo D; Monma Y; Chikatsu N; Shinagawa A
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2579-84. PubMed ID: 22189222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thalidomide and others: new treatment for myeloma].
    Malphettes M; Fermand JP
    Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
    [No Abstract]   [Full Text] [Related]  

  • 18. Thalidomide and thrombosis.
    Mehta P
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):464-5. PubMed ID: 16258433
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
    Pitini V; Arrigo C; Aloi G; Azzarello D; La Gattuta G
    Haematologica; 2002 Feb; 87(2):ELT07. PubMed ID: 11836184
    [No Abstract]   [Full Text] [Related]  

  • 20. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.